🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. Obinutuzumab

    United Therapeutics Europe Ltd

    Non-Hodgkin's Lymphoma

    phase 3 small molecule completed

    1 trial

  2. Ociperlimab, Ociperlimab, Pamiparib, Pamiparib, Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Solid tumors and hamatological malignancies

    phase 3 small molecule active

    1 trial

  3. Ocrelizumab

    Hoffmann-La Roche

    Multiple Sclerosis, Primary Progressive

    phase 3 small molecule active

    1 trial

  4. Ocrelizumab IV

    Hoffmann-La Roche

    Relapsing Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  5. Ocrelizumab, -, METHYLPREDNISOLONE , DEXAMETHASONE , Ocrevus, -

    Hoffmann-La Roche

    Neurological Disease

    phase 3 small molecule active

    1 trial

  6. Ocrevus 300 mg concentrate for solution for infusion, Paracetamol 500mg Tablets, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Placebo ocrelizumab, Diphenhydramine Hydrochloride Tablets 50 mg, Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsing Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  7. Ocrevus, ABP 692, Ocrevus 300 mg concentrate for solution for infusion

    Amgen

    Relapsing-remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  8. Octaplex 500 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Octaplex 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung

    Lacuna Pharma Pty Ltd

    Acute major bleeding in patients receiving DOAC therapy with factor Xa inhibitor

    phase 3 small molecule active

    1 trial

  9. Odevixibat

    Ipsen

    Biliary Atresia

    phase 3 small molecule active

    1 trial

  10. Odronextamab

    Regeneron UK Limited

    Follicular Lymphoma (FL)

    phase 3 small molecule active

    2 trials

  11. Odronextamab

    Regeneron UK Limited

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  12. Odronextamab

    ADC Therapeutics SA

    B-cell Non Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  13. Odronextamab

    Regeneron UK Limited

    Diffuse Large B-cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  14. Ofatumumab

    Novartis Pharmaceuticals

    Leukaemia, Lymphocytic, Chronic

    phase 3 mab terminated

    1 trial

  15. Olanzapine

    Janssen Cilag International NV

    Bipolar Disorder

    phase 3 small molecule completed

    1 trial

  16. Olaparib

    AstraZeneca

    Breast Cancer Metastatic

    phase 3 small molecule completed

    1 trial

  17. Olaparib 300mg tablets

    AstraZeneca

    Newly Diagnosed

    phase 3 small molecule active

    1 trial

  18. Olaparib 300mg tablets

    AstraZeneca

    Relapsed Ovarian Cancer

    phase 3 small molecule completed

    1 trial

  19. Olaparib, CISPLATIN , Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED , CARBOPLATIN

    Merck Sharp and Dohme

    Stage IV lung cancer condition

    phase 3 small molecule active

    1 trial

  20. Olaparib, ETOPOSIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pembrolizumab placebo (saline), Olaparib matching placebo (tablet), CARBOPLATIN , CISPLATIN , Olaparib

    Merck Sharp and Dohme

    Participants with Limited Stage-Small Cell Lung Cancer, who have received no prior anticancer therapy for their disease.

    phase 3 small molecule active

    1 trial

  21. Olodaterol (BI 1744)

    Boehringer Ingelheim

    Pulmonary Disease, Chronic Obstructive

    phase 3 small molecule completed

    2 trials

  22. Olokizumab

    International Peace Maternity and Child Health Hospital

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  23. Olokizumab 64 mg SC q4w

    International Peace Maternity and Child Health Hospital

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  24. Olokizumab 64mg q4w

    International Peace Maternity and Child Health Hospital

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources